Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevoflurane + propofol-Signe Sloth Madsen
- Development stage
- Unknown
- Lead developer
- Signe Sloth Madsen
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
sevoflurane + propofol-Signe Sloth Madsen refers to a specific clinical research study, DANA1 (Neuroplasticity Induced by General Anaesthesia), conducted by Signe Sloth Madsen at Rigshospitalet, University of Copenhagen. This randomized, cross-over trial compares the neuroplastic effects of two standard general anesthetics: sevoflurane, an inhaled halogenated ether, and propofol, an intravenous sedative-hypnotic. Sevoflurane acts as a positive allosteric modulator of GABA-A and glycine receptors and an antagonist of NMDA receptors. Propofol primarily functions as a positive allosteric modulator of the GABA-A receptor. The study utilizes 3-T magnetic resonance imaging (MRI) to investigate de novo neuroplastic changes in healthy volunteers following a two-hour maintenance phase of anesthesia, exploring associations between neuroplastic changes, clinical outcomes, and biochemical markers.
- Other names
- Neuroplasticity Induced by General AnaesthesiaSevoflurane-propofol
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)Glycine receptorGABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on sevoflurane + propofol-Signe Sloth Madsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevoflurane + propofol-Signe Sloth Madsen.